AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$120M+7.1% YoY

Gross Profit

$59M48.7% margin

Operating Income

$23M19.3% margin

Net Income

$16M13.2% margin

EPS (Diluted)

$0.30

QoQ Revenue Growth

-2.7%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$15M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$727M

Total Liabilities

$222M

Stockholders' Equity

$505M

Cash & Equivalents

$157M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$120M	$112M	+7.1%
Gross Profit	$59M	$51M	+14.3%
Operating Income	$23M	$25M	-6.2%
Net Income	$16M	$30M	-46.3%

Revenue Segments

Research and development services

$800,000100%

Geographic Segments

UNITED STATES

$118M98%

FRANCE

$2M1%

CHINA

$719,0001%

AMPH Q3 2022 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena